

1641
PATENT/Docket No.: 6322.N

Serial No.: 10/076,708

Page No. 1 #5

CERTIFICATE OF MAILING (37 CFR 1.8)

Date of Deposit with U.S. Postal Service: January 31, 2003

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington D.C. 20231.

Julie K. Lyons, Legal Assistant

Name of Person Mailing Paper

Julie K Lyons
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1641
Examiner : Unknown
Applicant(s) : SK Sharma, KB Rank
Serial No. : 10/076,708
Filed : 02/15/2002
For : ASSAYS FOR ASSESSING A β -TAU AGGREGATION

RECEIVED

FEB 05 2003

TECH CENTER 1600/2900

Commissioner of Patents and Trademarks
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL
UNDER 37 CFR 1.97 AND 1.98

Sir:

Information Disclosed. The information disclosed consists of the following:

☒ **Form PL-1449.** Provided herewith are copies of patent(s) and/or publication(s) as listed in the attached form PL-1449.

☐ At least to the extent required under §1.98(a)(3), a concise explanation of the relevance of references listed in form PL-1449 is:

- ☐ contained in the above-captioned specification as filed;
- ☐ provided in a communication enclosed with this paper;
- ☐ provided in the International Search Report enclosed with this paper; and/or
- ☐ not necessary as all of the references cited are in the English language.

- ☐ **Disclosure from Predecessor Application.** Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.53(d)) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, Serial No. filed, the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).


Basis for Consideration. This information disclosure statement is entitled to consideration by the Office under:

- ☐ **§1.97(b)**, as being filed within three months of the filing date of the above-captioned application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is/are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below.
- ☒ **§1.97(c)**, as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311. Consideration of this information disclosure statement at this time is requested for the reason checked below:
- ☒ **Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$240.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.**
- ☐ A statement as specified in 37 CFR 1.97(e) below.
- ☐ **§1.97(d)**, as being filed after the period specified in §1.97(c), but on or before payment of the issue fee and is accompanied by:
- ☐ **Authorization to charge Deposit Account No. 21-0718 the fee set forth in §1.17(i), \$130.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.**
- ☐ A petition requesting consideration of the information disclosure statement; and
- ☐ A statement as specified in 37 CFR 1.97 (e) below.
- ☐ **§1.97(e)**, this is a **supplemental information disclosure statement**. A prior information disclosure statement has already been filed. Applicant certifies, as provided in 37 CFR 1.97 (e), that

- ☐ Each new item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.
- ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing below, after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this statement.

Disclaimer. In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,



Edward F. Rehberg, Attorney
Registration No. 34,703

Date: 1-30-2003

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-7829 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316

Attachment(s)

- ☒ Form 1449 with copies of reference(s)
☐ Form 1449 from predecessor application (no references)
☐ Communication providing concise explanation of relevance
☐ International Search Report

LIST OF REFERENCES CITED BY APPLICANT <small>(Use several sheets if necessary)</small>				Atty. Docket No. 6322.N		Serial No. 10/076,708	
				Applicant SK Sharma, KB Rank			
				Filing Date 02/15/2002		Group 1641	

FEB 03 2003
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

RECEIVED
 FEB 05 2003
 TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AJ							
	AK							
	AL							
	AM							
	AN							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AO	Bancher, C. et al., "Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer's disease," Brain Research 477(1-2):90-99 [1989];
	AP	Bondareff, W. et al., "Molecular analysis of neurofibrillary degeneration in Alzheimer's Disease," American J. of Pathology 137(3):711-23 [1990];
	AQ	Caceres, A. et al., "Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons," Nature 343(6257):461-63 [1990];
	AR	Drubin, D.G. et al., "Tau protein function in living cells," J. Cell Biology 103(6 PT 2):2739-46 [1986];
	AS	Evans, D.B. et al., "Tau phosphorylation at Serine 396 and Serine 404 by human recombinant Tau protein kinase II inhibits Tau's ability to promote microtubule assembly," J. Biological Chemistry 275(32):24977-983 [2000];
	AT	Glenner, G.G. et al., "Alzheimer's Disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein," Biochemical and Biophysical Research Communications 120(3):885-90

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No.	Serial No.
		6322.N	10/076,708
		RECEIVED FEB 4 5 2003 TECH CENTER 1600/2900	
Applicant		SK Sharma, KB Rank	
Filing Date		02/15/2002	Group
[1984];			
AV	Goedert, M. et al., "Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau," PNAS 85:4051-55 [1988];		
AW	Goedert, M. et al., "Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's Disease," Neuron 3(4):519-26 [1989];		
AX	Goedert, M. et al., "Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization," The EMBO Journal 9(13): 4225-30 [1990];		
AY	Goedert, Michael, "Tau protein and the neurofibrillary pathology of Alzheimer's Disease," Trends in Neuroscience 16(11):460-65 [1993];		
AZ	Greenberg, S.G., et al., "A preparation of Alzheimer paired helical filaments that displays distinct τ proteins by polyacrylamide gel electrophoresis," PNAS 87(15):5827-31 [1990];		
BO	Himmler, Adolf, "Structure of the bovine tau gene: Alternatively spliced transcripts generate a protein family," Molecular and Cellular Biology 9(4):1389-96 [1989];		
BP	Horio, T. et al., "Visualization of the dynamic instability of individual microtubules by dark-field microscopy," Nature 321(6070):605-7 [1986];		
BQ	Kosik, K.S., "Tau protein and Alzheimer's disease," Current Opinion in Cell Biology 2(1):101-4 [1990];		
BR	Kosik, K.S., "Alzheimer plaques and tangles: advances on both fronts," TINS 14(6):218-19 [1991];		
BS	Kosik, K.S. et al., "Microtubule-associated protein tau (τ) is a major antigenic component of paired helical filaments in Alzheimer disease," PNAS 83(11):4044-48 [1986];		
BT	Ksiezak-Reding et al., "Structural stability of paired helical filaments requires microtubule-binding domains of tau: A model for self-association," Neuron 6(5):717-28 [1991];		
BU	Lee, G. et al., "The primary structure and heterogeneity of tau protein from mouse brain," Science 239(4837):285-88 [1988];		
BV	Lee, V.M.-Y., et al., "A68: A major subunit of paired helical filaments and derivatized forms of normal tau," Science 251(4994):675-78 [1991];		
BW	Lee, V.M.-Y., et al., "The disordered neuronal cytoskeleton in Alzheimer's disease," Current Opinion in Neurobiology 2(5):653-56 [1992];		
BX	Mailliot, C. et al., "Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes," FEBS Letters 433(3):201-04 [1998];		
BY	Spillantini, M.G. et al., "Tau protein pathology in neurodegenerative diseases," Trends in Neuroscience 21(10):428-33 [1998];		
BZ	Weingarten, M.D. et al., "A protein factor essential for microtubule assembly," PNAS 72(5):1858-62 [1975].		
CO			
CP			
Examiner		Date Considered	